2022³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Çϰ迬¼ö±³À° : 2022-06-17±³À°ÀÏÀÚ : 2022-06-17
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2022³âµµ ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Çϰ迬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 20,000¿ø/ºñȸ¿ø 30,000¿ø/ÁØȸ¿ø¹×±âŸ 10,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 30,000¿ø/ºñȸ¿ø 40,000¿ø/ÁØȸ¿ø ¹× ±âŸ 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 13:30~14:00 Children and adolescents ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 14:00~14:30 The elderly ÃßÀÏÇÑ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 14:30~15:00 Treatment strategy according to comorbid physical illnesses and safety/tolerability Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 13:30~14:00 Lamotrigine and lithium ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 14:00~14:30 Atypical antipsychotics ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 14:30~15:00 Antidepressants ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
ÈÞ½Ä 06-17 01:00~01:00 ()
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 15:15~15:45 ºñ¸¸°ú °Ç°ÇÑ Ã¼Çü°ü¸® ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 15:45~16:15 °Ç°±â´É½ÄÇ°(microbiome, etc)ÀÇ È°¿ë ÀÓ¼ö±Ù(¿¡½ºÁöÁ¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 06-17 ÄÁº¥¼ÇȦ 16:15~16:45 µÎÅë ÃÖ¿øÁØ(û´ã¼º¸ðÁ¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 15:15~15:45 WPA¡¯s and APA¡¯s responses to the COVID-19 pandemic ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 15:45~16:15 Potential interactions of 11 novel Covid-19 treatments with all psychiatric medications: A clinical perspective ½Åö¹Î(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-17 ´ëȸÀÇ½Ç 16:15~16:45 Managing behavioral and psychological symptoms of dementia during COVID-19: A clinician¡¯s guide ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)